Nanoparticles eradicating leukemia stem cells

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201400042C
Awardee
Awarding agency
Obligated
$224,363

Award facts

Opportunity
  • N43C04100527 Solicitation number
Contract value 100% obligated
$224,363.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 27 offers Basic Research
Pricing
Firm Fixed Price
Place of performance
Davis, CA, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope 1 $0
Original award $224,363

About this award

This is a $224,363 firm-fixed-price federal contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. government, to LP Therapeutics, Inc., a small business. The contract is for the development of nanoparticles to eradicate leukemia stem cells. The award has a completion date of July 31, 2015. This contract appears to be a standalone award, not associated with a larger contract vehicle.

Quick answers

Who was awarded contract HHSN261201400042C?

HHSN261201400042C was awarded to LP Therapeutics, Inc. by National Cancer Institute (National Institutes of Health) on September 18, 2014.

How much is contract HHSN261201400042C worth?

The government has obligated $224,363 on HHSN261201400042C.

Was contract HHSN261201400042C competed?

The extent of competition for HHSN261201400042C was full and open competition after exclusion of sources. The government received 27 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award